DK3484514T3 - Compositions and methods related to engineered fc constructs - Google Patents
Compositions and methods related to engineered fc constructs Download PDFInfo
- Publication number
- DK3484514T3 DK3484514T3 DK17803463.3T DK17803463T DK3484514T3 DK 3484514 T3 DK3484514 T3 DK 3484514T3 DK 17803463 T DK17803463 T DK 17803463T DK 3484514 T3 DK3484514 T3 DK 3484514T3
- Authority
- DK
- Denmark
- Prior art keywords
- engineered
- constructs
- compositions
- methods related
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340322P | 2016-05-23 | 2016-05-23 | |
| US201762443451P | 2017-01-06 | 2017-01-06 | |
| PCT/US2017/034084 WO2017205434A1 (en) | 2016-05-23 | 2017-05-23 | Compositions and methods related to engineered fc constructs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3484514T3 true DK3484514T3 (da) | 2024-01-29 |
Family
ID=60412547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17803463.3T DK3484514T3 (da) | 2016-05-23 | 2017-05-23 | Compositions and methods related to engineered fc constructs |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11155640B2 (da) |
| EP (2) | EP3464376A4 (da) |
| JP (4) | JP7045333B6 (da) |
| KR (3) | KR102462084B1 (da) |
| CN (4) | CN118206639A (da) |
| AU (2) | AU2017272111B2 (da) |
| BR (2) | BR112018074032A2 (da) |
| CA (2) | CA3025306A1 (da) |
| DK (1) | DK3484514T3 (da) |
| ES (1) | ES2973251T3 (da) |
| IL (3) | IL309293A (da) |
| PL (1) | PL3484514T3 (da) |
| SG (3) | SG10202011624SA (da) |
| WO (2) | WO2017205436A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016024780A2 (pt) * | 2014-05-02 | 2017-10-10 | Momenta Pharmaceutical Inc | composições e métodos relacionados com construtos de fc manipulados |
| JP7045333B6 (ja) | 2016-05-23 | 2022-05-06 | モメンタ ファーマシューティカルズ インコーポレイテッド | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| WO2018129255A1 (en) | 2017-01-06 | 2018-07-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
| US20210317227A1 (en) * | 2018-07-11 | 2021-10-14 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS |
| BR112021000427A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ctla-4 |
| WO2020014429A2 (en) * | 2018-07-11 | 2020-01-16 | Kurtagic Elma | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4 |
| JP2021531268A (ja) * | 2018-07-11 | 2021-11-18 | モメンタ ファーマシューティカルズ インコーポレイテッド | 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法 |
| CN113164592A (zh) * | 2018-07-11 | 2021-07-23 | 动量制药公司 | 与工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
| BR112021000383A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a pd-l1 |
| CN112969717A (zh) * | 2018-07-11 | 2021-06-15 | 动量制药公司 | 与工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
| MX2021000307A (es) * | 2018-07-11 | 2021-09-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética. |
| KR102661494B1 (ko) | 2019-03-08 | 2024-04-29 | 에이치엘만도 주식회사 | 랙구동형 동력 보조 조향장치 |
| EP4028415A1 (en) | 2019-09-13 | 2022-07-20 | CSL Behring Lengnau AG | Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders |
| EP4069292A1 (en) | 2019-12-06 | 2022-10-12 | CSL Behring Lengnau AG | Stable compositions of fc multimers |
| CN111808170A (zh) * | 2020-06-29 | 2020-10-23 | 江苏为真生物医药技术股份有限公司 | 多肽、hla-dr蛋白及其制备方法和应用 |
| US20220177549A1 (en) * | 2020-12-07 | 2022-06-09 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2556219B1 (fr) | 1983-12-07 | 1987-06-26 | Merieux Inst | Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines |
| US5426641A (en) | 1994-01-28 | 1995-06-20 | Bell Communications Research, Inc. | Adaptive class AB amplifier for TDMA wireless communications systems |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP2000515731A (ja) | 1996-06-14 | 2000-11-28 | スミスクライン・ビーチャム・コーポレイション | ６量体融合タンパク質およびその使用 |
| US20090074839A1 (en) | 1997-01-22 | 2009-03-19 | Marton Milankovits | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications |
| US7951917B1 (en) * | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2921260A1 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US20050089932A1 (en) * | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| US7803769B2 (en) | 2006-10-25 | 2010-09-28 | Amgen Inc. | OSK1 peptide analogs and pharmaceutical compositions |
| BRPI0620639A2 (pt) | 2006-12-21 | 2011-11-22 | Micromet Ag | anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos |
| EP2144930A1 (en) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| KR20100021601A (ko) | 2007-05-14 | 2010-02-25 | 바이오겐 아이덱 엠에이 인코포레이티드 | 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법 |
| CA2688490C (en) | 2007-06-01 | 2022-06-21 | Scott E. Strome | Immunoglobulin constant region fc receptor binding agents |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| CN107325182A (zh) | 2008-04-02 | 2017-11-07 | 宏观基因有限公司 | HER2/neu‑特异性抗体和其使用方法 |
| CA2739581A1 (en) | 2008-10-06 | 2010-04-15 | University Of Chicago | Compositions and methods related to bacterial eap, emp, and/or adsa proteins |
| US20100143353A1 (en) | 2008-12-04 | 2010-06-10 | Mosser David M | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME |
| EP2376105B1 (en) | 2008-12-18 | 2015-07-29 | Dana-Farber Cancer Institute, Inc. | Nkg2d-fc for immunotherapy |
| CA2750533A1 (en) | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
| CA2762302A1 (en) | 2009-05-20 | 2010-11-25 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
| US20120064008A1 (en) | 2009-05-20 | 2012-03-15 | Bruce Zetter | Compositions for the treatment of metastatic cancer and methods of use thereof |
| WO2011008517A2 (en) * | 2009-06-30 | 2011-01-20 | Research Development Foundation | Immunoglobulin fc polypeptides |
| US20120302737A1 (en) | 2009-09-16 | 2012-11-29 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| ES2672121T3 (es) | 2009-10-07 | 2018-06-12 | Macrogenics, Inc. | Polipéptidos que contienen región Fc que presentan una función efectora mejorada debido a alteraciones del grado de fucosilación, y métodos para su uso |
| AU2010321720B2 (en) | 2009-11-23 | 2017-03-02 | Amgen Inc. | Monomeric antibody Fc |
| GB0922209D0 (en) | 2009-12-18 | 2010-02-03 | Univ Nottingham | Proteins, nucleic acid molecules and compositions |
| BR112012029611A2 (pt) | 2010-05-21 | 2017-07-25 | Merrimack Pharmaceuticals Inc | proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico |
| CA2804280A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Chimeric clotting factors |
| DK2598533T3 (da) | 2010-07-28 | 2019-04-23 | Gliknik Inc | Fusionsproteiner af naturlige humane proteinfragmenter til på en ordnet måde at skabe multimeriserede immunoglobulin-FC-sammensætninger |
| JP2013537416A (ja) | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法 |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| MY162489A (en) * | 2010-12-23 | 2017-06-15 | Janssen Biotech Inc | ACTIVE PROTEASE-RESISTANT ANTIBODY Fc MUTANTS |
| IN2013MN01438A (da) | 2011-03-17 | 2015-06-12 | Univ Ramot | |
| EP2688909A2 (en) | 2011-03-25 | 2014-01-29 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
| EP2858659B1 (en) | 2012-06-08 | 2019-12-25 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
| WO2013192131A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
| MX2015002269A (es) * | 2012-08-20 | 2015-07-06 | Gliknik Inc | Moleculas con actividad de union al antigeno y al receptor fc gamma polivalente. |
| WO2014060712A1 (en) * | 2012-10-17 | 2014-04-24 | Liverpool School Of Tropical Medicine | Immunomodulatory proteins |
| CN104558194B (zh) * | 2013-10-17 | 2018-04-27 | 泰州迈博太科药业有限公司 | 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途 |
| JP2017504598A (ja) * | 2013-12-20 | 2017-02-09 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | 脂質化インクレチン受容体リガンドヒト免疫グロブリンｆｃ−領域融合ポリペプチド |
| CN110903398B (zh) | 2014-01-15 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
| KR20160104009A (ko) | 2014-01-15 | 2016-09-02 | 에프. 호프만-라 로슈 아게 | 변형된 FcRn-결합 성질을 갖는 Fc-영역 변이체 |
| TW201619188A (zh) | 2014-03-05 | 2016-06-01 | 優稀美生物醫藥公司 | 多聚體Ｆｃ蛋白質 |
| CA2939201A1 (en) | 2014-03-05 | 2015-09-11 | Ucb Biopharma Sprl | Multimeric fc proteins |
| BR112016024780A2 (pt) | 2014-05-02 | 2017-10-10 | Momenta Pharmaceutical Inc | composições e métodos relacionados com construtos de fc manipulados |
| EP3954703A3 (en) | 2014-05-29 | 2022-05-18 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| EP3423572B1 (en) | 2016-03-02 | 2023-11-29 | Momenta Pharmaceuticals, Inc. | Methods related to engineered fc constructs |
| JP7045333B6 (ja) * | 2016-05-23 | 2022-05-06 | モメンタ ファーマシューティカルズ インコーポレイテッド | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| WO2018129255A1 (en) | 2017-01-06 | 2018-07-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
-
2017
- 2017-05-23 JP JP2018561641A patent/JP7045333B6/ja active Active
- 2017-05-23 CN CN202410270902.0A patent/CN118206639A/zh active Pending
- 2017-05-23 CN CN201780045688.7A patent/CN109963869A/zh active Pending
- 2017-05-23 AU AU2017272111A patent/AU2017272111B2/en active Active
- 2017-05-23 SG SG10202011624SA patent/SG10202011624SA/en unknown
- 2017-05-23 KR KR1020187037334A patent/KR102462084B1/ko active IP Right Grant
- 2017-05-23 KR KR1020187037345A patent/KR102590061B1/ko active IP Right Grant
- 2017-05-23 SG SG11201810466PA patent/SG11201810466PA/en unknown
- 2017-05-23 BR BR112018074032-2A patent/BR112018074032A2/pt unknown
- 2017-05-23 DK DK17803463.3T patent/DK3484514T3/da active
- 2017-05-23 EP EP17803465.8A patent/EP3464376A4/en active Pending
- 2017-05-23 BR BR112018074056-0A patent/BR112018074056A2/pt unknown
- 2017-05-23 CA CA3025306A patent/CA3025306A1/en active Pending
- 2017-05-23 WO PCT/US2017/034087 patent/WO2017205436A1/en unknown
- 2017-05-23 IL IL309293A patent/IL309293A/en unknown
- 2017-05-23 JP JP2018561639A patent/JP2019519527A/ja not_active Withdrawn
- 2017-05-23 US US16/303,793 patent/US11155640B2/en active Active
- 2017-05-23 CN CN202210924611.XA patent/CN116063540A/zh active Pending
- 2017-05-23 SG SG11201810465RA patent/SG11201810465RA/en unknown
- 2017-05-23 WO PCT/US2017/034084 patent/WO2017205434A1/en unknown
- 2017-05-23 KR KR1020227037780A patent/KR102635635B1/ko active IP Right Grant
- 2017-05-23 AU AU2017272109A patent/AU2017272109A1/en active Pending
- 2017-05-23 CN CN201780045710.8A patent/CN109789203B/zh active Active
- 2017-05-23 CA CA3025310A patent/CA3025310A1/en active Pending
- 2017-05-23 IL IL263213A patent/IL263213B2/en unknown
- 2017-05-23 ES ES17803463T patent/ES2973251T3/es active Active
- 2017-05-23 IL IL263211A patent/IL263211B2/en unknown
- 2017-05-23 US US16/303,831 patent/US11623964B2/en active Active
- 2017-05-23 PL PL17803463.3T patent/PL3484514T3/pl unknown
- 2017-05-23 EP EP17803463.3A patent/EP3484514B1/en active Active
-
2021
- 2021-10-01 US US17/491,677 patent/US20220049019A1/en active Pending
-
2022
- 2022-01-27 JP JP2022010912A patent/JP2022068176A/ja active Pending
- 2022-03-18 JP JP2022044109A patent/JP7295301B2/ja active Active
-
2023
- 2023-04-10 US US18/298,131 patent/US20240067757A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286367A (en) | Compositions and methods relating to engineered fc constructs | |
| DK3484514T3 (da) | Compositions and methods related to engineered fc constructs | |
| ES2973207T3 (es) | Composiciones y procedimientos para modificar genomas utilizando Csm1 | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| BR112017000039A2 (pt) | composições agrícolas e aplicações que utilizam óleos essenciais | |
| DK3221363T3 (da) | Antistoffer mod cd73 og anvendelser deraf | |
| DK3169741T3 (da) | Forbedrede bindemiddelsammensætninger og anvendelser deraf | |
| DK2961831T3 (da) | Sammensætninger og fremgangsmåder til immunterapi | |
| DK3116533T3 (da) | Deletion af dystrophingenexon under anvendelse af genmanipulerede nukleaser | |
| DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
| KR20180084891A (ko) | 구조 조성물 및 방법 | |
| DK3018183T3 (da) | Halogenolefinbaseret sammensætning og anvendelse deraf | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| EP3423572A4 (en) | METHODS RELATING TO MANIPULATED FC CONSTRUCTS | |
| DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
| BR112016024191A2 (pt) | composições e aplicações agrícolas utilizando compostos minerais | |
| DK3183295T3 (da) | Fraktioneret alkyleret cyclodextrinsammensætning og fremgangsmåder til fremstilling og anvendelse af samme | |
| SG10202107391YA (en) | Compositions and methods related to engineered fc constructs | |
| DK3288379T3 (da) | Peptidsammensætninger og anvendelsesmåder | |
| BR112017012240A2 (pt) | métodos de preparação de composições contendo alcaloides e suas utilizações | |
| DK3113774T3 (da) | Sammensætninger af grapiprant og fremgangsmåder til anvendelse deraf | |
| DK3233104T3 (da) | Immunterapi-behandlinger og -sammensætninger | |
| DK3068428T3 (da) | Annexin-ii-variant-sammensætninger og fremgangsmåder | |
| DK3099314T3 (da) | Tolerogene sammensætninger og anvendelser deraf | |
| FR3026639B1 (fr) | Composition cosmetique |